Fingolimod start study for adults with relapsing MS
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study checks how safe and effective fingolimod is when adults with relapsing-remitting multiple sclerosis start it for the first time. It may help confirm whether this treatment works well and is tolerated in newly treated patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsing-remitting multiple sclerosis (a type of MS with flare-ups)
- You have never taken fingolimod before, and you are newly starting it now
- You are not currently taking any study drug or other investigational treatment
- You do not have certain heart rhythm problems (like specific heart blocks) unless you have a working pacemaker
- You do not have recent major heart/stroke events in the past 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This early phase trial tests a new treatment called GC012F for people with multiple sclerosis. It aims to see how safe and tolerable it is, and may offer a new option for those whose current treatments are not working well enough.
This study looks at how well fingolimod (Gilenya) works in people with relapsing-remitting multiple sclerosis (RRMS) in Greece. If you're already taking this medication, researchers will review your past medical data to see how it affects your MS over time.
This trial studies whether fingolimod can improve diabetes in adults with type 2 diabetes who are not yet on many medications. It will mainly check whether the drug is safe and whether it can help control blood sugar over time.
This trial tests a new drug called ublituximab to see if it can reduce flare-ups in children and teens who have relapsing multiple sclerosis. It aims to understand if the treatment is safe and effective for younger patients.
This study compares two oral medications, ozanimod and fingolimod, to see which one works better and is safer for children and teenagers with relapsing-remitting MS. Both drugs help reduce MS attacks and slow down the disease.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.